Cargando…

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

BACKGROUND: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. METHODS: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinato, David J., Ferrante, Daniela, Aguilar-Company, Juan, Bower, Mark, Salazar, Ramon, Mirallas, Oriol, Sureda, Anna, Bertuzzi, Alexia, Brunet, Joan, Lambertini, Matteo, Maluquer, Clara, Pedrazzoli, Paolo, Biello, Federica, Lee, Alvin J.X., Sng, Christopher C.T., Liñan, Raquel, Rossi, Sabrina, Carmona-García, M.Carmen, Sharkey, Rachel, Eremiev, Simeon, Rizzo, Gianpiero, Bain, Hamish DC., Yu, Tamara, Cruz, Claudia A., Perachino, Marta, Saoudi-Gonzalez, Nadia, Fort-Culillas, Roser, Doonga, Kris, Fox, Laura, Roldán, Elisa, Zoratto, Federica, Gaidano, Gianluca, Ruiz-Camps, Isabel, Bruna, Riccardo, Patriarca, Andrea, Shawe-Taylor, Marianne, Fusco, Vittorio, Martinez-Vila, Clara, Berardi, Rossana, Filetti, Marco, Mazzoni, Francesca, Santoro, Armando, Delfanti, Sara, Parisi, Alessandro, Queirolo, Paola, Aujayeb, Avinash, Rimassa, Lorenza, Prat, Aleix, Tabernero, Josep, Gennari, Alessandra, Cortellini, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124924/
https://www.ncbi.nlm.nih.gov/pubmed/35704976
http://dx.doi.org/10.1016/j.ejca.2022.04.036
_version_ 1784711833134825472
author Pinato, David J.
Ferrante, Daniela
Aguilar-Company, Juan
Bower, Mark
Salazar, Ramon
Mirallas, Oriol
Sureda, Anna
Bertuzzi, Alexia
Brunet, Joan
Lambertini, Matteo
Maluquer, Clara
Pedrazzoli, Paolo
Biello, Federica
Lee, Alvin J.X.
Sng, Christopher C.T.
Liñan, Raquel
Rossi, Sabrina
Carmona-García, M.Carmen
Sharkey, Rachel
Eremiev, Simeon
Rizzo, Gianpiero
Bain, Hamish DC.
Yu, Tamara
Cruz, Claudia A.
Perachino, Marta
Saoudi-Gonzalez, Nadia
Fort-Culillas, Roser
Doonga, Kris
Fox, Laura
Roldán, Elisa
Zoratto, Federica
Gaidano, Gianluca
Ruiz-Camps, Isabel
Bruna, Riccardo
Patriarca, Andrea
Shawe-Taylor, Marianne
Fusco, Vittorio
Martinez-Vila, Clara
Berardi, Rossana
Filetti, Marco
Mazzoni, Francesca
Santoro, Armando
Delfanti, Sara
Parisi, Alessandro
Queirolo, Paola
Aujayeb, Avinash
Rimassa, Lorenza
Prat, Aleix
Tabernero, Josep
Gennari, Alessandra
Cortellini, Alessio
author_facet Pinato, David J.
Ferrante, Daniela
Aguilar-Company, Juan
Bower, Mark
Salazar, Ramon
Mirallas, Oriol
Sureda, Anna
Bertuzzi, Alexia
Brunet, Joan
Lambertini, Matteo
Maluquer, Clara
Pedrazzoli, Paolo
Biello, Federica
Lee, Alvin J.X.
Sng, Christopher C.T.
Liñan, Raquel
Rossi, Sabrina
Carmona-García, M.Carmen
Sharkey, Rachel
Eremiev, Simeon
Rizzo, Gianpiero
Bain, Hamish DC.
Yu, Tamara
Cruz, Claudia A.
Perachino, Marta
Saoudi-Gonzalez, Nadia
Fort-Culillas, Roser
Doonga, Kris
Fox, Laura
Roldán, Elisa
Zoratto, Federica
Gaidano, Gianluca
Ruiz-Camps, Isabel
Bruna, Riccardo
Patriarca, Andrea
Shawe-Taylor, Marianne
Fusco, Vittorio
Martinez-Vila, Clara
Berardi, Rossana
Filetti, Marco
Mazzoni, Francesca
Santoro, Armando
Delfanti, Sara
Parisi, Alessandro
Queirolo, Paola
Aujayeb, Avinash
Rimassa, Lorenza
Prat, Aleix
Tabernero, Josep
Gennari, Alessandra
Cortellini, Alessio
author_sort Pinato, David J.
collection PubMed
description BACKGROUND: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. METHODS: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. RESULTS: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). CONCLUSIONS: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.
format Online
Article
Text
id pubmed-9124924
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-91249242022-05-23 Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer Pinato, David J. Ferrante, Daniela Aguilar-Company, Juan Bower, Mark Salazar, Ramon Mirallas, Oriol Sureda, Anna Bertuzzi, Alexia Brunet, Joan Lambertini, Matteo Maluquer, Clara Pedrazzoli, Paolo Biello, Federica Lee, Alvin J.X. Sng, Christopher C.T. Liñan, Raquel Rossi, Sabrina Carmona-García, M.Carmen Sharkey, Rachel Eremiev, Simeon Rizzo, Gianpiero Bain, Hamish DC. Yu, Tamara Cruz, Claudia A. Perachino, Marta Saoudi-Gonzalez, Nadia Fort-Culillas, Roser Doonga, Kris Fox, Laura Roldán, Elisa Zoratto, Federica Gaidano, Gianluca Ruiz-Camps, Isabel Bruna, Riccardo Patriarca, Andrea Shawe-Taylor, Marianne Fusco, Vittorio Martinez-Vila, Clara Berardi, Rossana Filetti, Marco Mazzoni, Francesca Santoro, Armando Delfanti, Sara Parisi, Alessandro Queirolo, Paola Aujayeb, Avinash Rimassa, Lorenza Prat, Aleix Tabernero, Josep Gennari, Alessandra Cortellini, Alessio Eur J Cancer Original Research BACKGROUND: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. METHODS: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. RESULTS: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). CONCLUSIONS: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer. Elsevier Ltd. 2022-08 2022-05-23 /pmc/articles/PMC9124924/ /pubmed/35704976 http://dx.doi.org/10.1016/j.ejca.2022.04.036 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Research
Pinato, David J.
Ferrante, Daniela
Aguilar-Company, Juan
Bower, Mark
Salazar, Ramon
Mirallas, Oriol
Sureda, Anna
Bertuzzi, Alexia
Brunet, Joan
Lambertini, Matteo
Maluquer, Clara
Pedrazzoli, Paolo
Biello, Federica
Lee, Alvin J.X.
Sng, Christopher C.T.
Liñan, Raquel
Rossi, Sabrina
Carmona-García, M.Carmen
Sharkey, Rachel
Eremiev, Simeon
Rizzo, Gianpiero
Bain, Hamish DC.
Yu, Tamara
Cruz, Claudia A.
Perachino, Marta
Saoudi-Gonzalez, Nadia
Fort-Culillas, Roser
Doonga, Kris
Fox, Laura
Roldán, Elisa
Zoratto, Federica
Gaidano, Gianluca
Ruiz-Camps, Isabel
Bruna, Riccardo
Patriarca, Andrea
Shawe-Taylor, Marianne
Fusco, Vittorio
Martinez-Vila, Clara
Berardi, Rossana
Filetti, Marco
Mazzoni, Francesca
Santoro, Armando
Delfanti, Sara
Parisi, Alessandro
Queirolo, Paola
Aujayeb, Avinash
Rimassa, Lorenza
Prat, Aleix
Tabernero, Josep
Gennari, Alessandra
Cortellini, Alessio
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
title Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
title_full Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
title_fullStr Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
title_full_unstemmed Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
title_short Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
title_sort vaccination against sars-cov-2 protects from morbidity, mortality and sequelae from covid19 in patients with cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124924/
https://www.ncbi.nlm.nih.gov/pubmed/35704976
http://dx.doi.org/10.1016/j.ejca.2022.04.036
work_keys_str_mv AT pinatodavidj vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT ferrantedaniela vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT aguilarcompanyjuan vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT bowermark vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT salazarramon vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT mirallasoriol vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT suredaanna vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT bertuzzialexia vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT brunetjoan vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT lambertinimatteo vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT maluquerclara vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT pedrazzolipaolo vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT biellofederica vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT leealvinjx vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT sngchristopherct vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT linanraquel vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT rossisabrina vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT carmonagarciamcarmen vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT sharkeyrachel vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT eremievsimeon vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT rizzogianpiero vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT bainhamishdc vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT yutamara vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT cruzclaudiaa vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT perachinomarta vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT saoudigonzaleznadia vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT fortculillasroser vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT doongakris vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT foxlaura vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT roldanelisa vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT zorattofederica vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT gaidanogianluca vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT ruizcampsisabel vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT brunariccardo vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT patriarcaandrea vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT shawetaylormarianne vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT fuscovittorio vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT martinezvilaclara vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT berardirossana vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT filettimarco vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT mazzonifrancesca vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT santoroarmando vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT delfantisara vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT parisialessandro vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT queirolopaola vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT aujayebavinash vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT rimassalorenza vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT prataleix vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT tabernerojosep vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT gennarialessandra vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT cortellinialessio vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer
AT vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer